cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2019.5.10258cardio-657Research ArticleОБЗОРREVIEWМаркеры фиброза сосудистой стенки ММП-9 и TIMP-1 у пациентов с ишемической болезнью сердца в сочетании с сахарным диабетом 2го типа и без негоMarkers of Vascular Wall Fibrosis Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Ischemic Heart Disease with and without Concomitant Type-2 Diabetes MellitusБеленковЮ. Н.BelenkovY. N.ПриваловаЕ. В.PrivalovaE. V.ЮсуповаА. О.IusupovaA. O.

PhD. 

Moscow

yusalya28@gmail.comЖитоА. В.ZhitoA. V.ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2019250520195956166Copyright © Kardiomag, 20192019KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/657

Распространенность ишемической болезни сердца (ИБС) и сахарного диабета (СД) 2го типа в мире и в Российской Федерации постоянно увеличивается. В связи с этим продолжается изучение механизмов патогенеза обоих заболеваний для профилактики осложнений и смерти. СД 2го типа вносит ощутимый вклад в прогрессирование течения ИБС. Одним из общих патогенетических звеньев обоих заболеваний является развитие выраженного фиброза сосудистой стенки. В статье представлен анализ исследований, посвященных определению роли металлопротеиназы-9 (ММП-9) и тканевого ингибитора матриксных метал лопротеиназ (TIMP-1) в формировании фиброза сосудистой стенки.  

The prevalence of ischemic heart disease (IHD) and diabetes mellitus type 2 (DM type 2) is permanently increasing both worldwide and in theRussian Federation. That is why studies of mechanisms of pathogenesis of both diseases is continuing for prevention of complications and mortality. DM type 2 contributes a lot to deterioration of IHD. One of pathogenetic features these two pathologies share is pronounced blood vessel wall fibrosis. In this review we present analysis of studies devoted to the determination of the role of metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 indevelopment of vascular wall fibrosis.   

ишемическая болезнь сердцасахарный диабет 2го типафиброз сосудистой стенкиметаллопротеиназа-9тканевый ингибитор металлопротеиназ-1ischemic heart diseasediabetes mellitus type 2blood vessel wall fibrosismetalloproteinase-9tissue inhibitor of metalloproteinases-1ReferencesWorld Health Organization. WHO: Russian Federation. Statistics. [Интернет] Available at: http://www.who.int/countries/rus/en/World Health Organization. WHO: Russian Federation. Statistics. [Интернет] Available at: http://www.who.int/countries/rus/en/World Health Organization. WHO: Global report on diabetes. [Интернет] 2016. Available at: http://www.who.int/diabetes/global-report/en/World Health Organization. WHO: Global report on diabetes. [Интернет] 2016. Available at: http://www.who.int/diabetes/global-report/en/Дедов И. И., Шестакова М. В., Викулова О. К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;20(1):13–41Dedov I. I., Shestakova M. V., Vikulova O. K. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes. 2017;20(1):13– 41. [Russian]Haffner SM. Cardiovascular risk factors and the prediabetic syndrome. Annals of Medicine. 1996;28(4):363–70. PMID: 8862692Haffner SM. Cardiovascular risk factors and the prediabetic syndrome. Annals of Medicine. 1996;28(4):363–70. PMID: 8862692Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28(12):2901–7. PMID: 16306552Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28(12):2901–7. PMID: 16306552Wannamethee SG. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90(12):1398–403. DOI: 10.1136/hrt.2003.026104Wannamethee SG. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90(12):1398–403. DOI: 10.1136/hrt.2003.026104Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8. DOI: 10.1136/bmj.38678.389583.7CHuxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8. DOI: 10.1136/bmj.38678.389583.7CVisse R, Nagase H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry. Circulation Research. 2003;92(8):827–39. DOI: 10.1161/01.RES.0000070112.80711.3DVisse R, Nagase H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry. Circulation Research. 2003;92(8):827–39. DOI: 10.1161/01.RES.0000070112.80711.3DPersic V, Bastiancic AL, Rosovic I, Raljevic D, Samsa DT, Bastiancic L et al. Correlation between immunological-inflammatory markers and endothelial disfunction in the early stage of coronary heart disease. Medical Hypotheses. 2018;115:72–6. DOI: 10.1016/j.mehy.2018.04.001Persic V, Bastiancic AL, Rosovic I, Raljevic D, Samsa DT, Bastiancic L et al. Correlation between immunological-inflammatory markers and endothelial disfunction in the early stage of coronary heart disease. Medical Hypotheses. 2018;115:72–6. DOI: 10.1016/j.mehy.2018.04.001Lahdentausta L, Leskela J, Winkelmann A, Tervahartiala T, Sorsa T, Pesonen E et al. Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence. Journal of Cardiovascular Translational Research. 2018;11(3):210– 20. DOI: 10.1007/s12265-018-9789-xLahdentausta L, Leskela J, Winkelmann A, Tervahartiala T, Sorsa T, Pesonen E et al. Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence. Journal of Cardiovascular Translational Research. 2018;11(3):210– 20. DOI: 10.1007/s12265-018-9789-xNewby AC. Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture. Physiological Reviews. 2005;85(1):1–31. DOI: 10.1152/physrev.00048.2003Newby AC. Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture. Physiological Reviews. 2005;85(1):1–31. DOI: 10.1152/physrev.00048.2003Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 1995;91(8):2125–31. PMID: 7697840Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 1995;91(8):2125–31. PMID: 7697840Cimmino G, Ragni M, Cirillo P, Petrillo G, Loffredo F, Chiariello M et al. C-reactive protein induces expression of matrix metalloproteinase9: A possible link between inflammation and plaque rupture. International Journal of Cardiology. 2013;168(2):981–6. DOI: 10.1016/j.ijcard.2012.10.040Cimmino G, Ragni M, Cirillo P, Petrillo G, Loffredo F, Chiariello M et al. C-reactive protein induces expression of matrix metalloproteinase9: A possible link between inflammation and plaque rupture. International Journal of Cardiology. 2013;168(2):981–6. DOI: 10.1016/j.ijcard.2012.10.040Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M et al. Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. Journal Of Investigative Medicine. 2003;51(5):295–300. DOI: 10.2310/6650.2003.3563Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M et al. Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. Journal Of Investigative Medicine. 2003;51(5):295–300. DOI: 10.2310/6650.2003.3563Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease. Circulation. 2003;107(12):1579–85. DOI: 10.1161/01.CIR.0000058700.41738.12Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease. Circulation. 2003;107(12):1579–85. DOI: 10.1161/01.CIR.0000058700.41738.12Mirhafez SR, Avan A, Tajfard M, Mohammadi S, Moohebati M, Fallah A et al. Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease. Journal of Clinical Laboratory Analysis. 2017;31(5):e22100. DOI: 10.1002/jcla.22100Mirhafez SR, Avan A, Tajfard M, Mohammadi S, Moohebati M, Fallah A et al. Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease. Journal of Clinical Laboratory Analysis. 2017;31(5):e22100. DOI: 10.1002/jcla.22100Yang DJ, Lee M-S, Kim WH, Park HW, Kim K-H, Kwon T-G et al. The impact of glucose control on coronary plaque composition in patients with diabetes mellitus. The Journal of Invasive Cardiology. 2013;25(3):137–41. PMID: 23468443Yang DJ, Lee M-S, Kim WH, Park HW, Kim K-H, Kwon T-G et al. The impact of glucose control on coronary plaque composition in patients with diabetes mellitus. The Journal of Invasive Cardiology. 2013;25(3):137–41. PMID: 23468443Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation. 2002;62(5):337–42. DOI: 10.1080/00365510260296483Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation. 2002;62(5):337–42. DOI: 10.1080/00365510260296483Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology. 1998;32(2):368–72. PMID: 9708462Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology. 1998;32(2):368–72. PMID: 9708462Weihrauch D, Lohr NL, Mraovic B, Ludwig LM, Chilian WM, Pagel PS et al. Chronic Hyperglycemia Attenuates Coronary Collateral Development and Impairs Proliferative Properties of Myocardial Interstitial Fluid by Production of Angiostatin. Circulation. 2004;109(19):2343–8. DOI: 10.1161/01.CIR.0000129225.67353.1FWeihrauch D, Lohr NL, Mraovic B, Ludwig LM, Chilian WM, Pagel PS et al. Chronic Hyperglycemia Attenuates Coronary Collateral Development and Impairs Proliferative Properties of Myocardial Interstitial Fluid by Production of Angiostatin. Circulation. 2004;109(19):2343–8. DOI: 10.1161/01.CIR.0000129225.67353.1FMahajan N, Malik N, Bahl A, Sharma Y, Dhawan V. Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. Molecular and Cellular Biochemistry. 2009;330(1–2):201–9. DOI: 10.1007/s11010-009-0134-1Mahajan N, Malik N, Bahl A, Sharma Y, Dhawan V. Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. Molecular and Cellular Biochemistry. 2009;330(1–2):201–9. DOI: 10.1007/s11010-009-0134-1Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris. Circulation. 2004;110(13):1747–53. DOI: 10.1161/01.CIR.0000142664.18739.92Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris. Circulation. 2004;110(13):1747–53. DOI: 10.1161/01.CIR.0000142664.18739.92Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, Nohara A et al. Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis. Clinical Chemistry and Laboratory Medicine. 2001;39(5):380–4. DOI: 10.1515/CCLM.2001.060Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, Nohara A et al. Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis. Clinical Chemistry and Laboratory Medicine. 2001;39(5):380–4. DOI: 10.1515/CCLM.2001.060Fitzsimmons PJ, Forough R, Lawrence ME, Gantt DS, Rajab MH, Kim H et al. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis. 2007;194(1):196–203. DOI: 10.1016/j.atherosclerosis.2006.07.027Fitzsimmons PJ, Forough R, Lawrence ME, Gantt DS, Rajab MH, Kim H et al. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis. 2007;194(1):196–203. DOI: 10.1016/j.atherosclerosis.2006.07.027Tanindi A, Sahinarslan A, Elbeg S, Cemri M. Association of matrix metalloproteinase-1, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1, and interleukin-6 with epicardial and myocardial perfusion: Coronary Artery Disease. 2011;22(4):253– 8. DOI: 10.1097/MCA.0b013e328343fc18Tanindi A, Sahinarslan A, Elbeg S, Cemri M. Association of matrix metalloproteinase-1, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1, and interleukin-6 with epicardial and myocardial perfusion: Coronary Artery Disease. 2011;22(4):253– 8. DOI: 10.1097/MCA.0b013e328343fc18Arsenault BJ, Kohli P, Lambert G, DeMicco DA, Laskey R, Messig MM et al. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology. 2016;118(4):494–8. DOI: 10.1016/j.amjcard.2016.05.044Arsenault BJ, Kohli P, Lambert G, DeMicco DA, Laskey R, Messig MM et al. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology. 2016;118(4):494–8. DOI: 10.1016/j.amjcard.2016.05.044Ceron CS, Luizon MR. Plasma matrix metalloproteinases in coronary artery disease patients. European Journal of Clinical Investigation. 2016;46(1):104–5. DOI: 10.1111/eci.12537Ceron CS, Luizon MR. Plasma matrix metalloproteinases in coronary artery disease patients. European Journal of Clinical Investigation. 2016;46(1):104–5. DOI: 10.1111/eci.12537Macarie RD, Vadana M, Ciortan L, Tucureanu MM, Ciobanu A, Vinereanu D et al. The expression of MMP‐1 and MMP‐9 is upregulated by smooth muscle cells after their cross‐talk with macrophages in high glucose conditions. Journal of Cellular and Molecular Medicine. 2018;22(9):4366–76. DOI: 10.1111/jcmm.13728Macarie RD, Vadana M, Ciortan L, Tucureanu MM, Ciobanu A, Vinereanu D et al. The expression of MMP‐1 and MMP‐9 is upregulated by smooth muscle cells after their cross‐talk with macrophages in high glucose conditions. Journal of Cellular and Molecular Medicine. 2018;22(9):4366–76. DOI: 10.1111/jcmm.13728Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U. Regulation and involvement of matrix metalloproteinases in vascular diseases. Frontiers in Bioscience (Landmark Edition). 2016;21:89–118. PMID: 26709763Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U. Regulation and involvement of matrix metalloproteinases in vascular diseases. Frontiers in Bioscience (Landmark Edition). 2016;21:89–118. PMID: 26709763Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(2):283–8. PMID: 12588772Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(2):283–8. PMID: 12588772Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Current Medicinal Chemistry. 2009;16(11):1349–54. PMID: 19355890Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Current Medicinal Chemistry. 2009;16(11):1349–54. PMID: 19355890Beton O, Arslan S, Acar B, Ozbilum N, Berkan O. Association between MMP-3 and MMP-9 polymorphisms and coronary artery disease. Biomedical Reports. 2016;5(6):709–14. DOI: 10.3892/br.2016.782Beton O, Arslan S, Acar B, Ozbilum N, Berkan O. Association between MMP-3 and MMP-9 polymorphisms and coronary artery disease. Biomedical Reports. 2016;5(6):709–14. DOI: 10.3892/br.2016.782Nakagawa P, Romero CA, Jiang X, D’Ambrosio M, Bordcoch G, Peterson EL et al. Ac-SDKP decreases mortality and cardiac rupture after acute myocardial infarction. PLOS ONE. 2018;13(1):e0190300. DOI: 10.1371/journal.pone.0190300Nakagawa P, Romero CA, Jiang X, D’Ambrosio M, Bordcoch G, Peterson EL et al. Ac-SDKP decreases mortality and cardiac rupture after acute myocardial infarction. PLOS ONE. 2018;13(1):e0190300. DOI: 10.1371/journal.pone.0190300

The authors declare that there are no conflicts of interest present.